Literature DB >> 14751852

Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor.

Allen D Everett1, Jill V Narron, Tamara Stoops, Hideji Nakamura, Amy Tucker.   

Abstract

Hepatoma-derived growth factor (HDGF) was previously identified as a developmentally regulated cardiovascular and renal gene that is mitogenic for vascular smooth muscle and aortic endothelial cells. As reciprocal interactions of smooth muscle and endothelial cells are necessary for vascular formation, we examined whether HDGF plays a role in angiogenesis. According to immunohistochemistry, HDGF was highly expressed in endothelial cells of nonmuscularized, forming blood vessels of the fetal lung. HDGF was also expressed in endothelial cells of small (20 microm) mature arteries and veins. By Western immunoblotting, HDGF was highly expressed by human pulmonary microvascular endothelial cells in vitro. Adenoviral overexpression of HDGF was mitogenic for human pulmonary microvascular endothelial cells in serum-free medium, stimulating a 1.75-fold increase in bromodeoxyuridine (BrdU) uptake and a twofold increase in cell migration. With the chick chorioallantoic membrane (CAM), a biologic assay for angiogenesis, exogenous recombinant HDGF significantly stimulated blood vessel formation and a dose-dependent reorganization of cells within the CAM into a more compact, linear alignment reminiscent of tube formation. According to double immunostaining for endothelial cells with a transforming growth factor-betaII receptor antibody and BrdU as a marker of cell proliferation, exogenous HDGF selectively stimulated endothelial cell BrdU uptake. HDGF also activated specific ERK1/2 signaling and did not overlap with VEGF SAPK/JNK, Akt-mediated pathways. We conclude that HDGF is a highly expressed vascular endothelial cell protein in vivo and is a potent endothelial mitogen and regulator of endothelial cell migration by mechanisms distinct from VEGF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751852     DOI: 10.1152/ajplung.00427.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  35 in total

1.  Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.

Authors:  Sen Guo; Hong-da Liu; Yan-Feng Liu; Lei Liu; Qiang Sun; Xi-Jun Cui
Journal:  Tumour Biol       Date:  2014-09-28

2.  The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension.

Authors:  Rebecca Johnson Kameny; Jeffrey R Fineman
Journal:  Am J Respir Crit Care Med       Date:  2016-11-15       Impact factor: 21.405

3.  Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.

Authors:  Anne-Sophie Belzacq-Casagrande; Florence Bachelot; Catherine De Oliveira; Séverine Coutadeur; Florence Maurier-Mahé; Emeline Throo; Cédric Chauvignac; Laure Pognante; Angélique Petibon; Thierry Taverne; Eric Beausoleil; Bertrand Leblond; Matthew P Pando; Laurent Désiré
Journal:  Invest New Drugs       Date:  2012-08-10       Impact factor: 3.850

4.  Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas.

Authors:  Shu-Shong Hsu; Chih-Hao Chen; Guei-Sheung Liu; Ming-Hong Tai; Jyh-Seng Wang; Jain-Ching Wu; Mei-Lang Kung; Elsa C Chan; Li-Feng Liu
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

5.  Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft.

Authors:  Zhi-kui Chen; Min-xian Cai; Jing Yang; Li-wu Lin; En-sheng Xue; Jing Huang; Hong-fen Wei; Xiu-juan Zhang; Li-ming Ke
Journal:  Med Oncol       Date:  2010-12-07       Impact factor: 3.064

6.  HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

Authors:  Jun Zhang; Ning Chen; Juan Qi; Baosen Zhou; Xueshan Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-27       Impact factor: 4.553

7.  Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2).

Authors:  Teruhisa Yamamoto; Hideji Nakamura; Weidong Liu; Ke Cao; Shohei Yoshikawa; Hirayuki Enomoto; Yoshinori Iwata; Noritoshi Koh; Masaki Saito; Hiroyasu Imanishi; Soji Shimomura; Hiroko Iijima; Toshikazu Hada; Shuhei Nishiguchi
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

8.  Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer.

Authors:  Yanyan Zhou; Nanxiang Zhou; Weiyi Fang; Jirong Huo
Journal:  Diagn Pathol       Date:  2010-09-16       Impact factor: 2.644

9.  Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.

Authors:  Hening Ren; Zuoming Chu; Li Mao
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

10.  Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy.

Authors:  Jun Zhao; Mark Z Ma; Hening Ren; Zhenqiu Liu; Martin J Edelman; Hong Pan; Li Mao
Journal:  Clin Cancer Res       Date:  2013-05-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.